Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015, 37772-37776 [2014-15549]
Download as PDF
37772
Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices
[USITC SE–14–023]
Sunshine Act Meetings
United
States International Trade Commission.
TIME AND DATE: July 11, 2014 at 11 a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–515–521
and 731–TA–1251–1257
(Preliminary)(Certain Steel Nails from
India, Korea, Malaysia, Oman, Taiwan,
Turkey, and Vietnam). The Commission
is currently scheduled to complete and
file its determinations on July 14, 2014;
views of the Commission are currently
scheduled to be completed and filed on
July 21, 2014.
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
By order of the Commission:
Issued: June 30, 2014.
William R. Bishop,
Supervisory Hearings and Information
Officer.
FOR FURTHER INFORMATION CONTACT:
Erika Gehrmann, Office of Diversion
Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone:
(202) 598–6812.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2014–15679 Filed 6–30–14; 4:15 pm]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Posting of Public Comments
Drug Enforcement Administration
[Docket No. DEA–393]
Proposed Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2015
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice with request for
comments.
AGENCY:
The Drug Enforcement
Administration proposes to establish the
2015 aggregate production quotas for
controlled substances in schedules I and
II of the Controlled Substances Act and
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:49 Jul 01, 2014
Interested persons may file
written comments on this notice in
accordance with 21 CFR 1303.11(c) and
1315.11(d). Electronic comments must
be submitted, and written comments
must be postmarked, on or before
August 1, 2014. Commenters should be
aware that the electronic Federal Docket
Management System will not accept
comments after midnight Eastern Time
on the last day of the comment period.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–393’’ on all electronic and
written correspondence. The DEA
encourages that all comments be
submitted electronically through the
Federal eRulemaking Portal which
provides the ability to type short
comments directly into the comment
field on the Web page or attach a file for
lengthier comments. Please go to http:
//www.regulations.gov and follow the
online instructions at that site for
submitting comments. Paper comments
that duplicate electronic submissions
are not necessary. Should you, however,
wish to submit written comments, in
lieu of electronic comments, they
should be sent via regular or express
mail to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
INTERNATIONAL TRADE
COMMISSION
Jkt 232001
Please note that all comments
received in response to this docket are
considered part of the public record and
will be made available for public
inspection online at https://
www.regulations.gov. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act
(FOIA) applies to all comments
received. If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want made publicly
available in the first paragraph of your
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
comment and identify what information
you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify the confidential
business information to be redacted
within the comment. If a comment has
so much confidential business
information that it cannot be effectively
redacted, all or part of that comment
may not be made publicly available.
Comments containing personal
identifying information or confidential
business information identified as
directed above will be made publicly
available in redacted form.
An electronic copy of this document
is available at https://
www.regulations.gov for easy reference.
If you wish to personally inspect the
comments and materials received or the
supporting documentation the DEA
used in preparing the proposed action,
these materials will be available for
public inspection by appointment. To
arrange a viewing, please see the FOR
FURTHER INFORMATION CONTACT
paragraph above.
Legal Authority
Section 306 of the Controlled
Substances Act (CSA), 21 U.S.C. 826,
requires the Attorney General to
determine the total quantity and
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. This
responsibility has been delegated to the
Administrator of the DEA pursuant to
28 CFR 0.100(b). The Administrator, in
turn, has redelegated that authority to
the Deputy Administrator, pursuant to
28 CFR part 0 subpart R, App.
Analysis for Proposed 2015 Aggregate
Production Quotas and Assessment of
Annual Needs
The proposed year 2015 aggregate
production quotas and assessment of
annual needs represent those quantities
of schedule I and II controlled
substances, and the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, to be
manufactured in the United States in
2015 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These quotas include
E:\FR\FM\02JYN1.SGM
02JYN1
Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices
imports of ephedrine, pseudoephedrine,
and phenylpropanolamine but do not
include imports of controlled
substances necessary to provide for the
medical, scientific, or other legitimate
needs of the United States.
In determining the proposed 2015
aggregate production quotas and
assessment of annual needs, the DEA
has taken into account the criteria that
the DEA is required to consider in
accordance with 21 U.S.C. 826(a), 21
CFR 1303.11 (aggregate production
quotas for controlled substances), and
21 CFR 1315.11 (assessment of annual
needs for ephedrine, pseudoephedrine,
and phenylpropanolamine). The DEA
proposes the aggregate production
quotas and assessment of annual needs
for 2015 by considering: (1) Total net
disposal of the class or chemical by all
manufacturers and chemical importers
during the current and two preceding
years; (2) trends in the national rate of
net disposal of the class or chemical; (3)
total actual (or estimated) inventories of
the class or chemical and of all
substances manufactured from the class
or chemical, and trends in inventory
accumulation; (4) projected demand for
such class or chemical as indicated by
procurement and chemical import
quotas requested in accordance with 21
CFR 1303.12, 1315.32, and 1315.34; and
(5) other factors affecting the medical,
scientific, research, and industrial needs
in the United States, lawful export
requirements, and reserve stocks, as the
Deputy Administrator finds relevant.
Other factors the DEA considered in
calculating the aggregate production
quotas, but not the assessment of annual
needs, include product development
requirements of both bulk and finished
dosage form manufacturers, and other
pertinent information. In determining
the proposed 2015 assessment of annual
needs, the DEA used the calculation
methodology previously described in
the 2010 and 2011 assessment of annual
needs (74 FR 60294, Nov. 20, 2009, and
75 FR 79407, Dec. 20, 2010,
respectively).
The DEA also specifically considered
that inventory allowances granted to
individual manufacturers may not
always result in the availability of
sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be concerning if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
available to provide for legitimate
public need. As such, the DEA proposes
to include in all schedule II aggregate
production quotas, and certain schedule
37773
I aggregate production quotas (gammahydroxybutyric acid and
tetrahydrocannabinols), an additional
25% of the estimated medical,
scientific, and research needs as part of
the amount necessary to ensure the
establishment and maintenance of
reserve stocks. The resulting established
aggregate production quotas will reflect
these included amounts. This action
will not affect the ability of
manufacturers to maintain inventory
allowances as specified by regulation.
The DEA expects that maintaining this
reserve in certain established aggregate
production quotas will mitigate adverse
public effects if an unforeseen event
resulted in substantial disruption to the
amount of controlled substances
available to provide for legitimate
public need, as determined by the DEA.
The DEA does not anticipate utilizing
the reserve in the absence of these
circumstances.
The Deputy Administrator, therefore,
proposes to establish the 2015 aggregate
production quotas for the following
schedule I and II controlled substances
and assessment of annual needs for the
list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Proposed established 2015
quotas (g)
Basic class
mstockstill on DSK4VPTVN1PROD with NOTICES
Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ...................................................................................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) .....................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) .......................................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ...................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ...........................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...................................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ...............................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073) ............................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ...........................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ...........................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ...........................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ......................................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ............................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ........................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ............................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ...........................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ....................................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) .......................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ......................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ...........................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ........................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ..........................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) .......................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ........................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ........................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ........................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ..............................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ..................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone) .........................................................................................................................
VerDate Mar<15>2010
17:49 Jul 01, 2014
Jkt 232001
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
15
15
15
15
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
15
30
15
30
15
15
37774
Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices
Proposed established 2015
quotas (g)
mstockstill on DSK4VPTVN1PROD with NOTICES
Basic class
2,5-Dimethoxy-4-ethylamphetamine (DOET) ......................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine .....................................................................................................................................
2,5-Dimethoxyamphetamine ................................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ................................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ..........................................................................................................
3,4,5-Trimethoxyamphetamine ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ..........................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) ...........................................................................................................................................
3-Fluoro-N-methylcathinone (3-FMC) ..................................................................................................................................................
3-Methylfentanyl ...................................................................................................................................................................................
3-Methylthiofentanyl .............................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ......................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ..................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) ..................................................................................................................................................
4-Methoxyamphetamine ......................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ......................................................................................................................................
4-Methylaminorex ................................................................................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ....................................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ........................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .........................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ...........................
5-Methoxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..................................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine .....................................................................................................................................................
Acetyl-alpha-methylfentanyl .................................................................................................................................................................
Acetyldihydrocodeine ...........................................................................................................................................................................
Acetylmethadol ....................................................................................................................................................................................
Allylprodine ..........................................................................................................................................................................................
Alphacetylmethadol ..............................................................................................................................................................................
alpha-Ethyltryptamine ..........................................................................................................................................................................
Alphameprodine ...................................................................................................................................................................................
Alphamethadol .....................................................................................................................................................................................
alpha-Methylfentanyl ............................................................................................................................................................................
alpha-Methylthiofentanyl ......................................................................................................................................................................
alpha-Methyltryptamine (AMT) ............................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ..............................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................
Aminorex ..............................................................................................................................................................................................
Benzylmorphine ...................................................................................................................................................................................
Betacetylmethadol ...............................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................
beta-Hydroxyfentanyl ...........................................................................................................................................................................
Betameprodine .....................................................................................................................................................................................
Betamethadol .......................................................................................................................................................................................
Betaprodine ..........................................................................................................................................................................................
Bufotenine ............................................................................................................................................................................................
Cathinone .............................................................................................................................................................................................
Codeine methylbromide .......................................................................................................................................................................
Codeine-N-oxide ..................................................................................................................................................................................
Desomorphine ......................................................................................................................................................................................
Diethyltryptamine .................................................................................................................................................................................
Difenoxin ..............................................................................................................................................................................................
Dihydromorphine ..................................................................................................................................................................................
Dimethyltryptamine ..............................................................................................................................................................................
Dipipanone ...........................................................................................................................................................................................
Fenethylline ..........................................................................................................................................................................................
gamma-Hydroxybutyric acid ................................................................................................................................................................
Heroin ..................................................................................................................................................................................................
Hydromorphinol ....................................................................................................................................................................................
Hydroxypethidine .................................................................................................................................................................................
Ibogaine ...............................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ........................................................................................................................................................
Marihuana ............................................................................................................................................................................................
Mescaline .............................................................................................................................................................................................
Methaqualone ......................................................................................................................................................................................
Methcathinone .....................................................................................................................................................................................
Methyldesorphine .................................................................................................................................................................................
Methyldihydromorphine ........................................................................................................................................................................
VerDate Mar<15>2010
17:49 Jul 01, 2014
Jkt 232001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
25
25
25
30
30
25
55
50
40
50
35
15
2
2
25
25
15
100
25
25
15
45
15
68
53
25
25
25
2
2
2
2
2
25
2
2
2
2
25
15
15
25
2
2
2
2
2
4
2
3
70
5
200
5
25
50
3,990,000
35
5
5
70,250,000
25
2
2
5
35
21,000
25
10
25
5
2
Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices
37775
Proposed established 2015
quotas (g)
Basic class
Morphine methylbromide .....................................................................................................................................................................
Morphine methylsulfonate ....................................................................................................................................................................
Morphine-N-oxide ................................................................................................................................................................................
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ........................................................................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) .....................................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) ..........................................
N,N-Dimethylamphetamine ..................................................................................................................................................................
Naphthylpyrovalerone (naphyrone) .....................................................................................................................................................
N-Benzylpiperazine ..............................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................
N-Ethylamphetamine ...........................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
Noracymethadol ...................................................................................................................................................................................
Norlevorphanol .....................................................................................................................................................................................
Normethadone .....................................................................................................................................................................................
Normorphine ........................................................................................................................................................................................
Phenomorphan ....................................................................................................................................................................................
Psilocybin .............................................................................................................................................................................................
Psilocyn ................................................................................................................................................................................................
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ........................................................................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ........................................................................................................
Tetrahydrocannabinols ........................................................................................................................................................................
Thiofentanyl .........................................................................................................................................................................................
Tilidine ..................................................................................................................................................................................................
Trimeperidine .......................................................................................................................................................................................
5
5
350
15
15
15
25
15
25
5
24
24
2
52
2
18
2
30
30
15
15
497,500
2
10
2
Schedule II
mstockstill on DSK4VPTVN1PROD with NOTICES
1-Phenylcyclohexylamine ....................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ....................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .........................................................................................................................................
Alfentanil ..............................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
Amobarbital ..........................................................................................................................................................................................
Amphetamine (for conversion) ............................................................................................................................................................
Amphetamine (for sale) .......................................................................................................................................................................
Carfentanil ............................................................................................................................................................................................
Cocaine ................................................................................................................................................................................................
Codeine (for conversion) .....................................................................................................................................................................
Codeine (for sale) ................................................................................................................................................................................
Dextropropoxyphene ............................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................................
Diphenoxylate ......................................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................................
Glutethimide .........................................................................................................................................................................................
Hydrocodone (for conversion) .............................................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................................................................
Hydromorphone ...................................................................................................................................................................................
Isomethadone ......................................................................................................................................................................................
levo-Alphacetylmethadol (LAAM) ........................................................................................................................................................
Levomethorphan ..................................................................................................................................................................................
Levorphanol .........................................................................................................................................................................................
Lisdexamfetamine ................................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Meperidine Intermediate-A ..................................................................................................................................................................
Meperidine Intermediate-B ..................................................................................................................................................................
Meperidine Intermediate-C ..................................................................................................................................................................
Metazocine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
5
5
2,687,500
17,625
3
25,125
21,875,000
37,500,000
19
240,000
50,000,000
46,125,000
19
101,375
1,337,500
174,375
3
2,108,750
3
137,500
99,625,000
6,250,000
5
4
5
3,375
29,750,000
6,250,000
6
11
6
19
31,875,000
34,375,000
2,061,375
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)].
Methylphenidate ...................................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Nabilone ...............................................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
VerDate Mar<15>2010
17:49 Jul 01, 2014
Jkt 232001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
83,750,000
91,250,000
62,500,000
18,750
17,500,000
37776
Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices
Proposed established 2015
quotas (g)
Basic class
Noroxymorphone (for sale) ..................................................................................................................................................................
Opium (powder) ...................................................................................................................................................................................
Opium (tincture) ...................................................................................................................................................................................
Oripavine ..............................................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxymorphone (for conversion) ............................................................................................................................................................
Oxymorphone (for sale) .......................................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phenazocine ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Phenylacetone .....................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Tapentadol ...........................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
1,475,000
112,500
687,500
22,750,000
8,350,000
137,500,000
21,875,000
7,750,000
35,000,000
6
19
3
9,375,000
3
3,750
215,003
6,255
12,500,000
125,000,000
List I Chemicals
Ephedrine (for conversion) ..................................................................................................................................................................
Ephedrine (for sale) .............................................................................................................................................................................
Phenylpropanolamine (for conversion) ................................................................................................................................................
Phenylpropanolamine (for sale) ...........................................................................................................................................................
Pseudoephedrine (for conversion) ......................................................................................................................................................
Pseudoephedrine (for sale) .................................................................................................................................................................
The Deputy Administrator further
proposes that aggregate production
quotas for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero. Pursuant to 21 CFR 1303.13 and 21
CFR 1315.13, upon consideration of the
relevant factors, the Deputy
Administrator may adjust the 2015
aggregate production quotas and
assessment of annual needs as
necessary.
mstockstill on DSK4VPTVN1PROD with NOTICES
Comments
In accordance with 21 CFR 1303.11(c)
and 1315.11(d), any interested person
may submit written comments on or
objections to these proposed
determinations. Based on comments
received in response to this notice, the
Deputy Administrator may hold a
public hearing on one or more issues
raised. 21 CFR 1303.11(c) and
1515.11(e). In the event the Deputy
Administrator decides to hold such a
hearing, the Deputy Administrator will
publish a notice of the hearing in the
Federal Register. After consideration of
any comments or objections, or after a
hearing, if one is held, the Deputy
Administrator will issue and publish in
the Federal Register a final order
establishing the 2015 aggregate
production quota for each basic class of
controlled substance and establishing
the assessment of annual needs for the
list I chemicals ephedrine,
VerDate Mar<15>2010
17:49 Jul 01, 2014
Jkt 232001
pseudoephedrine, and
phenylpropanolamine. 21 CFR
1303.11(c) and 1315.11(f).
Dated: June 26, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014–15549 Filed 7–1–14; 8:45 am]
BILLING CODE 4410–09–P
OFFICE OF MANAGEMENT AND
BUDGET
Draft 2014 Report to Congress on the
Benefits and Costs of Federal
Regulations and Unfunded Mandates
on State, Local, and Tribal Entities
Executive Office of the
President, Office of Management and
Budget.
ACTION: Notice of availability and
request for comments.
AGENCY:
The Office of Management
and Budget (OMB) requests comments
on its Draft 2014 Report to Congress on
the Benefits and Costs of Federal
Regulations, available at: https://
www.whitehouse.gov/omb/inforeg_
regpol_reports_congress/. The Draft
Report is divided into two parts. Part I
contains two chapters. Chapter I
examines the benefits and costs of major
Federal regulations issued in fiscal year
2013 and summarizes the benefits and
costs of major regulations issued
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
1,000,000
3,000,000
44,800,000
8,500,000
7,000
224,500,000
between October 2003 and September
2013. It also discusses regulatory
impacts on State, local, and tribal
governments, small business, wages,
and economic growth. Chapter II offers
recommendations for regulatory reform.
Part II summarizes agency compliance
with the Unfunded Mandates Reform
Act.
OMB requests that comments be
submitted electronically to OMB by
September 2, 2014 through
www.regulations.gov.
DATES: To ensure consideration of
comments as OMB prepares this Draft
Report for submission to Congress,
comments must be in writing and
received by September 2, 2014.
ADDRESSES: Submit comments by one of
the following methods:
• www.regulations.gov: Direct
comments to Docket ID OMB–2014–
0002
• Fax: (202) 395–7285
• Mail: Office of Information and
Regulatory Affairs, Office of
Management and Budget, Attn: Mabel
Echols, NEOB, Room 10202, 725 17th
Street NW., Washington, DC 20503. To
ensure that your comments are received,
we recommend that comments on this
draft report be electronically submitted.
All comments and recommendations
submitted in response to this notice will
be made available to the public,
including by posting them on OMB’s
Web site. For this reason, please do not
E:\FR\FM\02JYN1.SGM
02JYN1
Agencies
[Federal Register Volume 79, Number 127 (Wednesday, July 2, 2014)]
[Notices]
[Pages 37772-37776]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15549]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-393]
Proposed Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration proposes to establish the
2015 aggregate production quotas for controlled substances in schedules
I and II of the Controlled Substances Act and assessment of annual
needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: Interested persons may file written comments on this notice in
accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments
must be submitted, and written comments must be postmarked, on or
before August 1, 2014. Commenters should be aware that the electronic
Federal Docket Management System will not accept comments after
midnight Eastern Time on the last day of the comment period.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-393'' on all electronic and written correspondence.
The DEA encourages that all comments be submitted electronically
through the Federal eRulemaking Portal which provides the ability to
type short comments directly into the comment field on the Web page or
attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for
submitting comments. Paper comments that duplicate electronic
submissions are not necessary. Should you, however, wish to submit
written comments, in lieu of electronic comments, they should be sent
via regular or express mail to: Drug Enforcement Administration,
Attention: DEA Federal Register Representative/ODW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Erika Gehrmann, Office of Diversion
Control, Drug Enforcement Administration, 8701 Morrissette Drive,
Springfield, Virginia 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket
are considered part of the public record and will be made available for
public inspection online at https://www.regulations.gov. Such
information includes personal identifying information (such as your
name, address, etc.) voluntarily submitted by the commenter.
The Freedom of Information Act (FOIA) applies to all comments
received. If you want to submit personal identifying information (such
as your name, address, etc.) as part of your comment, but do not want
it to be made publicly available, you must include the phrase
``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your
comment. You must also place all the personal identifying information
you do not want made publicly available in the first paragraph of your
comment and identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be made publicly available, you
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the
first paragraph of your comment. You must also prominently identify the
confidential business information to be redacted within the comment. If
a comment has so much confidential business information that it cannot
be effectively redacted, all or part of that comment may not be made
publicly available. Comments containing personal identifying
information or confidential business information identified as directed
above will be made publicly available in redacted form.
An electronic copy of this document is available at https://www.regulations.gov for easy reference. If you wish to personally
inspect the comments and materials received or the supporting
documentation the DEA used in preparing the proposed action, these
materials will be available for public inspection by appointment. To
arrange a viewing, please see the FOR FURTHER INFORMATION CONTACT
paragraph above.
Legal Authority
Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826,
requires the Attorney General to determine the total quantity and
establish aggregate production quotas for each basic class of
controlled substance listed in schedules I and II and for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This
responsibility has been delegated to the Administrator of the DEA
pursuant to 28 CFR 0.100(b). The Administrator, in turn, has
redelegated that authority to the Deputy Administrator, pursuant to 28
CFR part 0 subpart R, App.
Analysis for Proposed 2015 Aggregate Production Quotas and Assessment
of Annual Needs
The proposed year 2015 aggregate production quotas and assessment
of annual needs represent those quantities of schedule I and II
controlled substances, and the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine, to be manufactured in the
United States in 2015 to provide for the estimated medical, scientific,
research, and industrial needs of the United States, lawful export
requirements, and the establishment and maintenance of reserve stocks.
These quotas include
[[Page 37773]]
imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do
not include imports of controlled substances necessary to provide for
the medical, scientific, or other legitimate needs of the United
States.
In determining the proposed 2015 aggregate production quotas and
assessment of annual needs, the DEA has taken into account the criteria
that the DEA is required to consider in accordance with 21 U.S.C.
826(a), 21 CFR 1303.11 (aggregate production quotas for controlled
substances), and 21 CFR 1315.11 (assessment of annual needs for
ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA proposes
the aggregate production quotas and assessment of annual needs for 2015
by considering: (1) Total net disposal of the class or chemical by all
manufacturers and chemical importers during the current and two
preceding years; (2) trends in the national rate of net disposal of the
class or chemical; (3) total actual (or estimated) inventories of the
class or chemical and of all substances manufactured from the class or
chemical, and trends in inventory accumulation; (4) projected demand
for such class or chemical as indicated by procurement and chemical
import quotas requested in accordance with 21 CFR 1303.12, 1315.32, and
1315.34; and (5) other factors affecting the medical, scientific,
research, and industrial needs in the United States, lawful export
requirements, and reserve stocks, as the Deputy Administrator finds
relevant. Other factors the DEA considered in calculating the aggregate
production quotas, but not the assessment of annual needs, include
product development requirements of both bulk and finished dosage form
manufacturers, and other pertinent information. In determining the
proposed 2015 assessment of annual needs, the DEA used the calculation
methodology previously described in the 2010 and 2011 assessment of
annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20,
2010, respectively).
The DEA also specifically considered that inventory allowances
granted to individual manufacturers may not always result in the
availability of sufficient quantities to maintain an adequate reserve
stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24.
This would be concerning if a natural disaster or other unforeseen
event resulted in substantial disruption to the amount of controlled
substances available to provide for legitimate public need. As such,
the DEA proposes to include in all schedule II aggregate production
quotas, and certain schedule I aggregate production quotas (gamma-
hydroxybutyric acid and tetrahydrocannabinols), an additional 25% of
the estimated medical, scientific, and research needs as part of the
amount necessary to ensure the establishment and maintenance of reserve
stocks. The resulting established aggregate production quotas will
reflect these included amounts. This action will not affect the ability
of manufacturers to maintain inventory allowances as specified by
regulation. The DEA expects that maintaining this reserve in certain
established aggregate production quotas will mitigate adverse public
effects if an unforeseen event resulted in substantial disruption to
the amount of controlled substances available to provide for legitimate
public need, as determined by the DEA. The DEA does not anticipate
utilizing the reserve in the absence of these circumstances.
The Deputy Administrator, therefore, proposes to establish the 2015
aggregate production quotas for the following schedule I and II
controlled substances and assessment of annual needs for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Proposed
established
Basic class 2015 quotas
(g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 15
tetramethylcyclopropyl)methanone (UR-144)..............
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 15
tetramethylcyclopropyl)methanone (XLR11)...............
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 15
(butylone).............................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 15
(pentylone)............................................
1-(1-Phenylcyclohexyl)pyrrolidine....................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)....... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)...... 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................... 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45
200)...................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)................. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 45
and RCS-8).............................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)................. 45
1-Methyl-4-phenyl-4-propionoxypiperidine................ 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)...... 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)....... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)...... 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)....... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)....... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)... 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)..... 45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)..... 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)........ 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)....... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)....... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)................ 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
Cimbi-36)..............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)....... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
Cimbi-82)..............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)......... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
Cimbi-5)...............................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone)....... 15
[[Page 37774]]
2,5-Dimethoxy-4-ethylamphetamine (DOET)................. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine.............. 25
2,5-Dimethoxyamphetamine................................ 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- 30
T-4)...................................................
3,4,5-Trimethoxyamphetamine............................. 25
3,4-Methylenedioxyamphetamine (MDA)..................... 55
3,4-Methylenedioxymethamphetamine (MDMA)................ 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............ 40
3,4-Methylenedioxy-N-methylcathinone (methylone)........ 50
3,4-Methylenedioxypyrovalerone (MDPV)................... 35
3-Fluoro-N-methylcathinone (3-FMC)...................... 15
3-Methylfentanyl........................................ 2
3-Methylthiofentanyl.................................... 2
4-Bromo-2,5-dimethoxyamphetamine (DOB).................. 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............. 25
4-Fluoro-N-methylcathinone (4-FMC)...................... 15
4-Methoxyamphetamine.................................... 100
4-Methyl-2,5-dimethoxyamphetamine (DOM)................. 25
4-Methylaminorex........................................ 25
4-Methyl-N-ethylcathinone (4-MEC)....................... 15
4-Methyl-N-methylcathinone (mephedrone)................. 45
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)....... 15
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 68
phenol.................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)...
5-Methoxy-3,4-methylenedioxyamphetamine................. 25
5-Methoxy-N,N-diisopropyltryptamine..................... 25
5-Methoxy-N,N-dimethyltryptamine........................ 25
Acetyl-alpha-methylfentanyl............................. 2
Acetyldihydrocodeine.................................... 2
Acetylmethadol.......................................... 2
Allylprodine............................................ 2
Alphacetylmethadol...................................... 2
alpha-Ethyltryptamine................................... 25
Alphameprodine.......................................... 2
Alphamethadol........................................... 2
alpha-Methylfentanyl.................................... 2
alpha-Methylthiofentanyl................................ 2
alpha-Methyltryptamine (AMT)............................ 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)............. 15
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)............ 15
Aminorex................................................ 25
Benzylmorphine.......................................... 2
Betacetylmethadol....................................... 2
beta-Hydroxy-3-methylfentanyl........................... 2
beta-Hydroxyfentanyl.................................... 2
Betameprodine........................................... 2
Betamethadol............................................ 4
Betaprodine............................................. 2
Bufotenine.............................................. 3
Cathinone............................................... 70
Codeine methylbromide................................... 5
Codeine-N-oxide......................................... 200
Desomorphine............................................ 5
Diethyltryptamine....................................... 25
Difenoxin............................................... 50
Dihydromorphine......................................... 3,990,000
Dimethyltryptamine...................................... 35
Dipipanone.............................................. 5
Fenethylline............................................ 5
gamma-Hydroxybutyric acid............................... 70,250,000
Heroin.................................................. 25
Hydromorphinol.......................................... 2
Hydroxypethidine........................................ 2
Ibogaine................................................ 5
Lysergic acid diethylamide (LSD)........................ 35
Marihuana............................................... 21,000
Mescaline............................................... 25
Methaqualone............................................ 10
Methcathinone........................................... 25
Methyldesorphine........................................ 5
Methyldihydromorphine................................... 2
[[Page 37775]]
Morphine methylbromide.................................. 5
Morphine methylsulfonate................................ 5
Morphine-N-oxide........................................ 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide 15
(AKB48)................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 15
indazole-3-carboxamide (ADB-PINACA)....................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)- 15
1H-indazole-3-carboxamide (AB-FUBINACA)................
N,N-Dimethylamphetamine................................. 25
Naphthylpyrovalerone (naphyrone)........................ 15
N-Benzylpiperazine...................................... 25
N-Ethyl-1-phenylcyclohexylamine......................... 5
N-Ethylamphetamine...................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine................. 24
Noracymethadol.......................................... 2
Norlevorphanol.......................................... 52
Normethadone............................................ 2
Normorphine............................................. 18
Phenomorphan............................................ 2
Psilocybin.............................................. 30
Psilocyn................................................ 30
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 15
(5-fluoro-PB-22; 5F-PB-22).............................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; 15
QUPIC).................................................
Tetrahydrocannabinols................................... 497,500
Thiofentanyl............................................ 2
Tilidine................................................ 10
Trimeperidine........................................... 2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................. 5
1-Piperidinocyclohexanecarbonitrile..................... 5
4-Anilino-N-phenethyl-4-piperidine (ANPP)............... 2,687,500
Alfentanil.............................................. 17,625
Alphaprodine............................................ 3
Amobarbital............................................. 25,125
Amphetamine (for conversion)............................ 21,875,000
Amphetamine (for sale).................................. 37,500,000
Carfentanil............................................. 19
Cocaine................................................. 240,000
Codeine (for conversion)................................ 50,000,000
Codeine (for sale)...................................... 46,125,000
Dextropropoxyphene...................................... 19
Dihydrocodeine.......................................... 101,375
Diphenoxylate........................................... 1,337,500
Ecgonine................................................ 174,375
Ethylmorphine........................................... 3
Fentanyl................................................ 2,108,750
Glutethimide............................................ 3
Hydrocodone (for conversion)............................ 137,500
Hydrocodone (for sale).................................. 99,625,000
Hydromorphone........................................... 6,250,000
Isomethadone............................................ 5
levo-Alphacetylmethadol (LAAM).......................... 4
Levomethorphan.......................................... 5
Levorphanol............................................. 3,375
Lisdexamfetamine........................................ 29,750,000
Meperidine.............................................. 6,250,000
Meperidine Intermediate-A............................... 6
Meperidine Intermediate-B............................... 11
Meperidine Intermediate-C............................... 6
Metazocine.............................................. 19
Methadone (for sale).................................... 31,875,000
Methadone Intermediate.................................. 34,375,000
Methamphetamine......................................... 2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)].
------------------------------------------------------------------------
Methylphenidate......................................... 83,750,000
Morphine (for conversion)............................... 91,250,000
Morphine (for sale)..................................... 62,500,000
Nabilone................................................ 18,750
Noroxymorphone (for conversion)......................... 17,500,000
[[Page 37776]]
Noroxymorphone (for sale)............................... 1,475,000
Opium (powder).......................................... 112,500
Opium (tincture)........................................ 687,500
Oripavine............................................... 22,750,000
Oxycodone (for conversion).............................. 8,350,000
Oxycodone (for sale).................................... 137,500,000
Oxymorphone (for conversion)............................ 21,875,000
Oxymorphone (for sale).................................. 7,750,000
Pentobarbital........................................... 35,000,000
Phenazocine............................................. 6
Phencyclidine........................................... 19
Phenmetrazine........................................... 3
Phenylacetone........................................... 9,375,000
Racemethorphan.......................................... 3
Remifentanil............................................ 3,750
Secobarbital............................................ 215,003
Sufentanil.............................................. 6,255
Tapentadol.............................................. 12,500,000
Thebaine................................................ 125,000,000
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).............................. 1,000,000
Ephedrine (for sale).................................... 3,000,000
Phenylpropanolamine (for conversion).................... 44,800,000
Phenylpropanolamine (for sale).......................... 8,500,000
Pseudoephedrine (for conversion)........................ 7,000
Pseudoephedrine (for sale).............................. 224,500,000
------------------------------------------------------------------------
The Deputy Administrator further proposes that aggregate production
quotas for all other schedule I and II controlled substances included
in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors,
the Deputy Administrator may adjust the 2015 aggregate production
quotas and assessment of annual needs as necessary.
Comments
In accordance with 21 CFR 1303.11(c) and 1315.11(d), any interested
person may submit written comments on or objections to these proposed
determinations. Based on comments received in response to this notice,
the Deputy Administrator may hold a public hearing on one or more
issues raised. 21 CFR 1303.11(c) and 1515.11(e). In the event the
Deputy Administrator decides to hold such a hearing, the Deputy
Administrator will publish a notice of the hearing in the Federal
Register. After consideration of any comments or objections, or after a
hearing, if one is held, the Deputy Administrator will issue and
publish in the Federal Register a final order establishing the 2015
aggregate production quota for each basic class of controlled substance
and establishing the assessment of annual needs for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. 21 CFR
1303.11(c) and 1315.11(f).
Dated: June 26, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-15549 Filed 7-1-14; 8:45 am]
BILLING CODE 4410-09-P